

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

ANNOUNCEMENT

This is a voluntary announcement made by Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”).

The Company had received an investor’s email forward from the Shanghai Stock Exchange on 2 December 2013, pursuant to which the Shanghai Stock Exchange requested the Company to respond to the query raised by that investor in relation to the Company’s breaching of undertakings made in publication in May 2003 and failure to make a prompt disclosure in respect of relevant experimental statistics of I Ib clinical research of the therapeutic dual-plasmid HBV DNA vaccine* (治療性雙質粒HBV DNA疫苗)”. After investigation, the relevant information is set out as follows:

1. After investigation, the Company confirmed that it had never made any undertakings regarding the publication of relevant information of the I Ib clinical research of the therapeutic dual-plasmid HBV DNA vaccine in its periodical reports or any announcements;
2. Currently, the data of the I Ib clinical research of the therapeutic dual-plasmid HBV DNA vaccine is under calculation, the results of which is expected to be disclosed within ten days. The Company will make announcement immediately once the results are available.

The Board of

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 5 December 2013

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Ms. Cheng Ning and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.

* For identification purpose only